Common Contracts

EX-10.5 2 apvo-ex105_281.htm EX-10.5 AMENDED AND RESTATED MANUFACTURING SERVICES AGREEMENT BY AND BETWEEN EMERGENT BIOSOLUTIONS INC. AND APTEVO THERAPEUTICS INC. DATED AS OF SEPTEMBER 28, 2017 Page

Manufacturing Services Agreement • May 5th, 2020 • Delaware

• Contract Type
  Manufacturing Services Agreement
• Filed
  May 5th, 2020
• Jurisdiction
  Delaware

AMENDED AND RESTATED MANUFACTURING SERVICES AGREEMENT BY AND BETWEEN EMERGENT BIOSOLUTIONS INC. AND APTEVO THERAPEUTICS INC. DATED AS OF SEPTEMBER 28, 2017

Manufacturing Services Agreement • March 13th, 2018 • Aptevo Therapeutics Inc. • Pharmaceutical preparations • Delaware

• Contract Type
  Manufacturing Services Agreement
• Filed
  March 13th, 2018
• Company
  Aptevo Therapeutics Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

This AMENDED AND RESTATED MANUFACTURING SERVICES AGREEMENT, dated as of September 28, 2017 (this “Agreement”), is made and entered into by and between Emergent BioSolutions Inc., a Delaware corporation (“Emergent”), and Aptevo Therapeutics Inc., a Delaware corporation (“Aptevo”). Aptevo and Emergent are referred to together as the “Parties” and individually as a “Party.” Unless otherwise defined in this Agreement, all capitalized terms used in this Agreement shall have the meaning set forth in the Separation and Distribution Agreement (“SDA”) or, if not therein, in the Transition Services Agreement (“TSA”), or, if not therein, in the Canadian Distributor Agreement (“CDA”), or, if not therein, in the Product Licensing Agreement (the “PLA”), or, if not therein, in the Trademark License Agreement (“TLA”), each dated as of July 29, 2016, by and between Emergent and Aptevo. The Parties acknowledge and agree that this Agreement is an Ancillary Agreement under the SDA.